A retrospective analysis of discontinuation rates and reasons for discontinuation in multiple sclerosis patients treated with delayed-release dimethyl fumarate (Biogen ONE Support Program)

被引：0
|
作者：
Vorobeychik, G. [1 ]
Potts, J. [2 ]
Smith, M. [3 ]
Vlaicu, M. [3 ]
机构：
[1] Fraser Hlth Multiple Sclerosis Clin, Burnaby, BC, Canada
[2] Biogen, Cambridge, MA USA
[3] Biogen, Mississauga, ON, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P638
引用
收藏
页码：301 / 302
页数：2
相关论文
共 50 条
  • [31] Pregnancy outcomes from an international registry of patients treated with delayed-release dimethyl fumarate
    Everage, N. J.
    Jones, C. C.
    Hellwig, K.
    Rog, D.
    Liu, S.
    Mou, J.
    Prada, C.
    Hanna, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 295 - 295
  • [32] Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate
    Mayer, Lori
    Fink, Mary Kay
    Sammarco, Carrie
    Laing, Lisa
    DRUG SAFETY, 2018, 41 (04) : 347 - 356
  • [33] Safety and effectiveness of delayed-release dimethyl fumarate maintained over 4-years in multiple sclerosis patients treated in routine medical practice
    Pandey, K.
    Giles, K.
    Balashov, K.
    Macdonell, R.
    Windsheimer, J.
    Chen, H.
    Parks, B.
    Mendoza, J. P.
    Jones, C. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 318 - 319
  • [34] Pregnancy reports and outcomes from multiple sclerosis patients primarily treated with peginterferon beta-1a and delayed-release dimethyl fumarate in Germany
    Niemczyk, G.
    Begus-Nahrmann, Y.
    Herold, S.
    Grundler, M. -T.
    Rosenstroem, H.
    Sedlmeier, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 732 - 732
  • [35] MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE
    Arnold, Douglas L.
    Fox, Robert J.
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Yousry, Tarek
    MacManus, David
    Yang, Lili
    Riester, Katherine
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [36] Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice, an updated analysis of the ESTEEM Study
    Pandey, Krupa
    Giles, Kathryn
    Balashov, Konstantin
    Macdonell, Richard
    Windsheimer, Jorg
    Martinez, Mikel
    Bozin, Ivan
    Jiang, Xiaotong
    Lyons, Jennifer
    Mokliatchouk, Oksana
    Okai, Annette
    NEUROLOGY, 2023, 100 (17)
  • [37] A pharmacokinetic study of delayed-release dimethyl fumarate to evaluate cerebrospinal fluid penetration in patients with secondary progressive multiple sclerosis
    Edwards, K.
    Penner, N.
    Rogge, M.
    Sheikh, S.
    Zhu, B.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 784 - 785
  • [38] Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Fox, Robert J.
    Zhang, Annie
    Meltzer, Leslie
    Kurukulasuriya, Nuwan C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 57 - 66
  • [39] Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing multiple sclerosis
    Fox, E. J.
    Vasquez, A.
    Grainger, W.
    Ma, T. S.
    von Hehn, C.
    Walsh, J.
    Li, J.
    Zambrano, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 205 - 205
  • [40] Clinical efficacy of delayed-release dimethyl fumarate in Hispanic patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
    Hernandez, L.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Okwuokeny, M.
    Zhang, A.
    Rana, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E306
12345